SynthesisBMC pulmonary medicine2026
Prognostic significance of CEP55 expression in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is one of the primary contributors to global cancer mortality. Elevated expression of centrosomal protein 55 (CEP55) is frequently observed in NSCLC and is closely linked to tumorigenesis and disease progression. However, the prognostic value of CEP55 in NSCLC has not been fully established. The current meta-analysis assessed how increased CEP55 expression may influence prognosis in patients diagnosed with NSCLC.
methodsEligible studies were retrieved via a systematic search across major biomedical databases. Additionally, validation cohorts were retrieved from the Gene Expression Omnibus (GEO) database. To quantify the prognostic relevance of CEP55, hazard ratios (HRs) and 95% confidence intervals (CIs) were synthesized from eligible studies. The Newcastle-Ottawa Scale was leveraged to assess the methodological quality of the included studies. This review was registered with PROSPERO (CRD420251006676).
resultsA total of 18 independent study cohorts (6 literature-derived and 12 database-derived) involving 4,829 patients were included. The meta-analysis revealed that elevated CEP55 expression was significantly associated with poorer overall survival (OS) in NSCLC patients [HR = 1.22, 95% CI: 1.13–1.32]. Subgroup analysis by histological subtype showed that CEP55 serves as an independent predictor of poor OS in lung adenocarcinoma (LUAD) [HR = 1.28, 95% CI: 1.20–1.37], whereas its prognostic utility in lung squamous cell carcinoma (LUSC) was not statistically significant [HR = 0.98, 95% CI: 0.90–1.06]. Multivariate analysis further confirmed CEP55 as an independent risk factor for LUAD, with its prognostic impact being particularly evident in early-stage disease characteristics—including Stage I, limited tumor infiltration (T1–T2), and the absence of distant metastasis (M0)—as well as in patients with negative surgical margins or those who had not received chemotherapy.
conclusionCEP55 may act as a potential indicator for predicting disease progression and survival outcomes in NSCLC, particularly in LUAD. Further investigation into the underlying mechanisms of CEP55 is necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.